Detalles de la búsqueda
1.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med
; 388(23): 2145-2158, 2023 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36972026
2.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
N Engl J Med
; 385(23): 2123-2131, 2021 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874631
3.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Future Oncol
; 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38501262
4.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer
; 129(12): 1846-1855, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060236
5.
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Int J Gynecol Cancer
; 33(6): 971-981, 2023 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792166
6.
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Int J Gynecol Cancer
; 33(11): 1733-1742, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37931976
7.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 381(25): 2391-2402, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562799
8.
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.
Future Oncol
; 18(23): 2505-2536, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35791804
9.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740262
10.
PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.
N Engl J Med
; 389(9): 867, 2023 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646695
11.
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Int J Cancer
; 146(2): 439-448, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31381147
12.
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 159(2): 442-448, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32981695
13.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
N Engl J Med
; 375(22): 2154-2164, 2016 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717299
14.
Efficacy and safety of niraparib as maintenance treatment in older patients (≥â¯70â¯years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Gynecol Oncol
; 152(3): 560-567, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30638768
15.
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Int J Gynecol Cancer
; 29(7): 1141-1147, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31420414
16.
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Lancet Oncol
; 19(8): 1117-1125, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30026000
17.
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 17(1): 78-89, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26590673
18.
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Gynecol Oncol
; 140(3): 443-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26740259
19.
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
BMC Med Ethics
; 17(1): 63, 2016 10 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27769273
20.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncol
; 16(8): 928-36, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26115797